Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
Ellen M. Ginzler(State University of New York), Gerald B. Appel(Columbia University Irving Medical Center), Joan T. Merrill(Oklahoma Medical Research Foundation), Gary S. Gilkeson(Medical University of South Carolina), Cynthia Aranow(Feinstein Institute for Medical Research), Jill P. Buyon(New York University), Michelle Petri(Johns Hopkins University), Mimi Kim(Albert Einstein College of Medicine), Mary Anne Dooley(University of North Carolina at Chapel Hill), Daniel J. Wallace(Cedars-Sinai Medical Center), Michael H. Weisman(Cedars-Sinai Medical Center)
Cited by 1,126
Related Papers
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
A Pathogenetic Role for TNFα in the Syndrome of Cachexia, Arthritis, and Autoimmunity Resulting from Tristetraprolin (TTP) Deficiency
|Immunity|1996|766
Autoimmune-Associated Congenital Heart Block: Demographics, Mortality, Morbidity and Recurrence Rates Obtained From a National Neonatal Lupus Registry
|Journal of the American College of Cardiology|1998|748
Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus
|Arthritis & Rheumatism|2010|481
Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study
|Annals of the Rheumatic Diseases|2010|460